NCT06533605View on ClinicalTrials.gov

Phase I Clinical Study to Evaluate the Safety and Efficacy of SSGJ-706 Monotherapy for Patients With Advanced Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2024

Primary Completion Date

July 30, 2025

Study Completion Date

August 31, 2025

Conditions

Advanced Solid Tumors Patients

Interventions

DRUG

SSGJ-706

Bispecific antibody

All Listed Sponsors

lead

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

INDUSTRY

NCT06533605 - Phase I Clinical Study to Evaluate the Safety and Efficacy of SSGJ-706 Monotherapy for Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter